Open AccessCharacteristics and Outcome of Pediatric Patients Enrolled in Phase I Oncology Trials
Author(s) -
Kim AeRang,
Fox Elizabeth,
Warren Katherine,
Blaney Susan M.,
Berg Stacey L.,
Adamson Peter C.,
Libucha Madeleine,
Byrley Elena,
Balis Frank M.,
Widemann Brigitte C.
Publication year - 2008
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2008-0046
Subject(s) - medicine , clinical trial , toxicity , concomitant , clinical endpoint , refractory (planetary science) , oncology , surgery , physics , astrobiology
Learning Objectives After completing this course, the reader will be able to: Describe the characteristics of pediatric patients who have enrolled in phase I trials over the past decade. Describe the relationship between enrollment characteristics and the risk for toxicity in a phase I trial. Identify the potential risks and benefits for pediatric patients with refractory solid tumors in phase I trials.Access and take the CME test online and receive 1 AMA PRA Category 1 Credit ™ at CME.TheOncologist.com